MainReads
← Details
Firstline treatment with ruxolitinib versus best available therapy in patients with polycythemia vera: results from the randomized RuxoBEAT trial.
Koschmieder S, Isfort S, Teichmann LL, Schafhausen P, Heidel FH, Crodel C, Hochhaus A, Griesshammer M, Sockel K, Jost PJ, Walther D, Döhner K, Göthert JR, Radsak M, Augustin M, Becker H, Giagounidis A, Schaich M, Klausmann M, von Bubnoff N, Stegelmann F, Kortmann M, Zentis M, Frank J, Hagemeier A, Hellmich M, Brümmendorf TH, German Study Group for Myeloproliferative Neoplasms (GSG-MPN)
/
-
Loading document from repository...
Unable to Display Document
The online reader was unable to display this document directly. This may occur if the repository host is temporarily unreachable, or if security restrictions (CORS) prevent embedded viewing.